Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors.
暂无分享,去创建一个
Hoan Vu | Sally-Ann Poulsen | Thomas E Prisinzano | Jennifer L. Martin | B. Collins | K. Lovell | T. Prisinzano | M. McLeish | N. Drinkwater | Nyssa Drinkwater | Michael J McLeish | Jennifer L Martin | S. Poulsen | Gary L Grunewald | Brett M Collins | Kimberly M Lovell | Kevin R Criscione | H. Vu | G. L. Grunewald | K. R. Criscione
[1] Michèle N Schulz,et al. Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.
[2] Christine L Gee,et al. Mode of binding of methyl acceptor substrates to the adrenaline-synthesizing enzyme phenylethanolamine N-methyltransferase: implications for catalysis. , 2005, Biochemistry.
[3] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[4] R. Lister,et al. Antagonism of ethanol intoxication in rats by inhibitors of phenylethanolamine N-methyltransferase. , 1990, Alcoholism, clinical and experimental research.
[5] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[6] T Neumann,et al. SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.
[7] E. Freire. Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.
[8] Brett A Tounge,et al. Ligand efficiency and fragment-based drug discovery. , 2009, Drug discovery today.
[9] Masaki Tomimoto,et al. Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[10] T. Earnest,et al. Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. , 2006, Journal of medicinal chemistry.
[11] Masaya Orita,et al. Advances in fragment-based drug discovery platforms , 2009, Expert opinion on drug discovery.
[12] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[13] Vicki L. Nienaber,et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.
[14] Jennifer L. Martin,et al. Structural, mutagenic, and kinetic analysis of the binding of substrates and inhibitors of human phenylethanolamine N-methyltransferase. , 2005, Journal of medicinal chemistry.
[15] C. Kaiser,et al. Studies on the mechanism of phenylethanolamine-N-methyl-transferase inhibition by a dichloro-substituted benzimidazole. , 1972, Biochemical pharmacology.
[16] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[17] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[18] Sally-Ann Poulsen,et al. Direct screening of a dynamic combinatorial library using mass spectrometry , 2006, Journal of the American Society for Mass Spectrometry.
[19] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[20] Peter Kuhn,et al. Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. , 2002, Journal of synchrotron radiation.
[21] E. Neafsey,et al. Phenylethanolamine N-methyltransferase has β-carboline 2N-methyltransferase activity: hypothetical relevance to Parkinson’s disease , 2002, Neurochemistry International.
[22] A. W. Schüttelkopf,et al. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.
[23] W Bruce Turnbull,et al. On the value of c: can low affinity systems be studied by isothermal titration calorimetry? , 2003, Journal of the American Chemical Society.
[24] Edgar Jacoby,et al. Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.
[25] M. McLeish,et al. Getting the adrenaline going: crystal structure of the adrenaline-synthesizing enzyme PNMT. , 2001, Structure.
[26] Munish Puri,et al. Molecular recognition of physiological substrate noradrenaline by the adrenaline-synthesizing enzyme PNMT and factors influencing its methyltransferase activity. , 2009, The Biochemical journal.
[27] Kristin A. Sannes-Lowery,et al. Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes , 2006, Nature Reviews Drug Discovery.
[28] F. Kuehl,et al. Inhibition of adrenal phenethanolamine N-methyltransferase by substituted benzimidazoles. , 1970, Journal of medicinal chemistry.
[29] M. Spetea,et al. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities. , 2005, Journal of medicinal chemistry.
[30] N. Leonard,et al. Sulfonate Salts of Substituted Benzimidazoles1 , 1947 .
[31] E. Masliah,et al. Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function , 2004, Journal of Neural Transmission.
[32] C. Murray,et al. The rise of fragment-based drug discovery. , 2009, Nature chemistry.
[33] Christine L Gee,et al. Enzyme adaptation to inhibitor binding: a cryptic binding site in phenylethanolamine N-methyltransferase. , 2007, Journal of medicinal chemistry.
[34] Paul G Wyatt,et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.
[35] R. Fuller,et al. Inhibition of phenylethanolamine N-methyltransferase by benzylamines. 2. In vitro and in vivo studies with 2,3-dichloro- -methylbenzylamine. , 1973, Journal of medicinal chemistry.
[36] S. Hughes,et al. Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. , 2007, Journal of medicinal chemistry.
[37] T. Blundell,et al. Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. , 2006, Journal of medicinal chemistry.
[38] R. Quinn,et al. Direct Screening of Natural Product Extracts Using Mass Spectrometry , 2008, Journal of biomolecular screening.
[39] K. Perry,et al. Inhibition of brain epinephrine synthesis by 3,4-dichlorophenylethanolamine, a competitive substrate for norepinephrine N-methyltransferase. , 1983, Biochemical pharmacology.
[40] Gerhard Klebe,et al. Adding calorimetric data to decision making in lead discovery: a hot tip , 2010, Nature Reviews Drug Discovery.
[41] D. Erlanson. Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.
[42] R. Fuller. Pharmacology of brain epinephrine neurons. , 1982, Annual review of pharmacology and toxicology.
[43] F. A. Romero,et al. Exploring the active site of phenylethanolamine N-methyltransferase: 3-alkyl-7-substituted-1,2,3,4-tetrahydroisoquinoline inhibitors. , 2005, Bioorganic & medicinal chemistry.
[44] Jean-Pierre Marquette,et al. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. , 2002, Journal of medicinal chemistry.
[45] M. Johnson,et al. Evidence for the involvement of central epinephrine systems in the regulation of luteinizing hormone, prolactin, and growth hormone release in female rats. , 1982, Endocrinology.